Publication details

Zpráva o ukončení klinického hodnocení NISCI v České republice

Title in English Report on the clinical trial termination in the Czech Republic NISCI
Authors

KUBÁTOVÁ Jana KŘÍŽ Jiří

Year of publication 2022
MU Faculty or unit

Faculty of Medicine

Citation
Description The report overviews the clinical trial „Antibodies against Nogo-A to enhance plasticity, regeneration and functional recovery after acute spinal cord injury“ conducted in the Czech Republic. The trial was terminated in CZE on 4 October 2022. The primary aim of the trial was to assess the efficacy of monoclonal antibody NG-101 in patients with spinal cord injury. The trial sponsor is University Zurich (Switzerland), and the legal representative for the EU is University Hospital Heidelberg (Germany).

You are running an old browser version. We recommend updating your browser to its latest version.

More info